Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/65610
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorSchool of Nursing-
dc.creatorBressington, D-
dc.creatorMui, J-
dc.creatorTse, ML-
dc.creatorGray, R-
dc.creatorCheung, EFC-
dc.creatorChien, WT-
dc.date.accessioned2017-05-22T02:08:55Z-
dc.date.available2017-05-22T02:08:55Z-
dc.identifier.urihttp://hdl.handle.net/10397/65610-
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rights© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en_US
dc.rightsThe following publication Bressington, D., Mui, J., Tse, M. L., Gray, R., Cheung, E. F. C., & Chien, W. T. (2016). Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders : a cross-sectional study. BMC Psychiatry, 16, 411, 1-14 is available at https://dx.doi.org/10.1186/s12888-016-1121-1en_US
dc.subjectAntipsychoticsen_US
dc.subjectCardiometabolic healthen_US
dc.subjectCardiovascular disease risken_US
dc.subjectDefined daily doseen_US
dc.subjectObesityen_US
dc.subjectPolypharmacyen_US
dc.subjectQRISK®2en_US
dc.subjectQuality of lifeen_US
dc.subjectSchizophreniaen_US
dc.subjectSF-12en_US
dc.titleCardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders : a cross-sectional studyen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.epage14-
dc.identifier.volume16-
dc.identifier.doi10.1186/s12888-016-1121-1-
dcterms.abstractBackground: People with schizophrenia-spectrum disorders (SSD) often have high levels of obesity and poor cardiometabolic health. Certain types of antipsychotics have been shown to contribute towards weight gain and there is some equivocal evidence that obesity is related to poor health-related quality of life (HRQoL) in people with SSD. It is also still uncertain if antipsychotic polypharmacy/higher doses of antipsychotics are linked with HRQoL and/or increased risk of obesity/Cardiovascular Disease (CVD). Therefore, this study aimed to examine potential relationships between prescribed antipsychotic medication regimens, cardiometabolic health risks and HRQoL in community-based Chinese people with SSD.-
dcterms.abstractMethod: This cross-sectional study reports the results of baseline measurements of a random sample of patients in an ongoing controlled trial of physical health intervention for people with severe mental illness. Data from these randomly-selected participants (n=82) were analysed to calculate 10-year CVD relative-risk (using QRISK®2 score), estimate the prevalence of metabolic syndrome and contextualize patients' prescribed antipsychotics (types, combinations and Daily Defined Dose equivalent). Patients self-reported their HRQoL (SF12v2) and their obesity condition was assessed by waist-circumference and Body Mass Index (BMI).-
dcterms.abstractResults: Two-thirds of patients had a BMI ≥23kg/m2, almost half were centrally obese and 29% met the criteria for metabolic syndrome. The individual relative-risk of CVD ranged from 0.62 to 15, and 13% had a moderate-to-high 10-year CVD risk score. Regression models showed that lower physical HRQoL was predicted by higher BMI and lower mental HRQoL. Higher Defined Daily Dose, clozapine, younger age and male gender were found to explain 40% of the variance in CVD relative risk. Conclusion: The findings indicate that cardiometabolic health risks in people with SSD may be more common than those reported in the general Hong Kong population. The results also provide further support for the need to consider antipsychotic polypharmacy and higher doses of antipsychotics as factors that may contribute towards cardiometabolic risk in Chinese patients with SSD. Clinicians in Hong Kong should consider using routine CVD risk screening, and be aware that younger male patients who are taking clozapine and prescribed higher Defined Daily Dose seem to have the highest relative-risk of CVD. Trial registration: Clinicaltrials.gov NCT02453217. Prospectively registered on 19th May 2015.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationBMC psychiatry, 2016, v. 16, 411, p. 1-14-
dcterms.isPartOfBMC psychiatry-
dcterms.issued2016-
dc.identifier.isiWOS:000388637400002-
dc.identifier.scopus2-s2.0-84998717727-
dc.identifier.ros2016000161-
dc.identifier.eissn1471-244X-
dc.identifier.artn411-
dc.identifier.rosgroupid2016000160-
dc.description.ros2016-2017 > Academic research: refereed > Publication in refereed journal-
dc.description.validate201804_a bcma-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_IR/PIRAen_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Bressington_Cardiometabolic_Health_Prescribed.pdf527.36 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

158
Last Week
1
Last month
Citations as of Mar 24, 2024

Downloads

91
Citations as of Mar 24, 2024

SCOPUSTM   
Citations

30
Last Week
0
Last month
Citations as of Mar 28, 2024

WEB OF SCIENCETM
Citations

23
Last Week
0
Last month
Citations as of Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.